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ABSTRACT
Introduction: Patient-reported outcome mea-
sures (PROs) specific for genital psoriasis
(GenPs) have not been described.
Methods: In this cross-sectional, qualitative
study in patients with moderate-to-severe
GenPs, we sought to develop a PRO useful for
GenPs symptom assessment. A literature review
was performed to identify relevant psoriasis or
GenPs symptoms and existing PROs that may be
useful in the evaluation of symptom severity in
GenPs patients. The literature review findings
were discussed with clinicians, and then
patients with GenPs.
Results: Relevant psoriasis or GenPs symptoms
from the literature review included itch, pain,
scaling, redness/erythema, and stinging/burn-
ing. The validity of these symptoms for GenPs
and potentially relevant PROs was corroborated
by clinical experts. After gap analysis, a draft
symptom scale consisting of Numeric Rating
Scale (NRS) items was constructed. We then
conducted interviews with GenPs patients
(n = 20) to support content validity and use of
the draft symptom NRS items in routine prac-
tice and in clinical trials. Participants identified
and confirmed relevant symptoms and evalu-
ated the utility of the draft PRO. A new PRO was
developed: the Genital Psoriasis Symptoms
Scale (GPSS). Cognitive debriefing and cultural
adaptation/translation interviews with a second
group of patients confirmed cultural appropri-
ateness of the GPSS.
Conclusion: The GPSS may be useful for
assessing symptoms before, during, and after
treatment in routine clinical practice and in
clinical trials involving patients with GenPs.
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PLAIN LANGUAGE SUMMARY
People with psoriasis experience raised red pat-
ches of skin. The raised red patches of skin can
occur anywhere on the body, including the
genital area. When raised red patches of skin are
on the genital area, it can be upsetting,
uncomfortable, and painful. The raised red
patches of skin may burn, itch, bleed, and hurt.
The purpose of this research was to develop a set
of questions that doctors and researchers can
use to determine common symptoms experi-
enced by patients with genital psoriasis and to
measure the severity of these symptoms. On the
basis of research and interviews with doctors
and patients, we determined that genital psori-
asis can cause itching, pain, discomfort, sting-
ing, burning, redness, scaling, and cracking. The
new questionnaire has eight questions, one for
each symptom. For example, one question asks
patients to rate the severity of itching from 0
(no itch) to 10 (worst itch imaginable) in their
genital area. Patients can be asked to answer
these questions before, during, and after treat-
ment with different medicines. Doctors and
researchers can use patients’ answers to help
determine how well a medicine is helping the
patient.
INTRODUCTION
A substantial number (29–63%) of patients with
chronic plaque psoriasis report having psoriatic
lesions in the genital area at some time during
the course of their disease [1–3]. Genital psori-
asis (GenPs) sometimes lacks the characteristic
scale present at other bodily sites because of
moistness and maceration [4, 5], and fissures
and erosions may be present [6, 7]. Because
GenPs may not have the appearance of classic
chronic plaque psoriasis, GenPs may be
misidentified by the patient (e.g., as a sexually
transmitted disease [2]).
In a survey of patients with GenPs (n = 354),
87% reported itch, and 39% reported pain [3].
After correcting for overall psoriasis severity,
psoriasis patients with genital lesions report
worse health-related quality of life than patients
without genital involvement [3, 8]. Moreover,
psoriasis patients with genital lesions report
greater feelings of stigmatization and lower self-
esteem than patients with lesions in visible
areas [9]. There have been substantial advances
in other aspects of psoriasis research, but
information on the identification and treat-
ment of GenPs in routine dermatologic practice
has been sparse; patients with GenPs are often
not examined or questioned for this manifes-
tation and its psychosexual implications
[10–13].
Few data exist for the efficacy of treatment
for psoriasis in the genital area despite the
considerable morbidity and psychosocial
impact associated with this condition. Topical
treatments for GenPs include steroids and vita-
min D analogues [2, 10]. Systemic therapy is
generally reserved for second-line treatment or
more severe cases [10, 14]. Although numerous
patient-reported outcome measures (PROs) are
available for measuring symptoms of general
psoriasis [15, 16], none specifically pertain to
GenPs. In this study, we report development
and content validation of a new PRO that
measures symptoms specific to GenPs. The
newly developed Genital Psoriasis Symptoms
Scale (GPSS) may have applicability for use in
clinical trials and in standard clinical practice
for patients with GenPs.
METHODS
Study Objectives and Design
The purpose of this cross-sectional study was to
support content validity and the use of existing
or adapted PROs with GenPs patients. First, a
literature review was performed to identify
psoriasis- or GenPs-associated symptoms and
existing PROs that could be used to assess the
severity of these symptoms in patients with
GenPs. The results of the literature review were
confirmed by clinicians. We then performed a
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gap analysis to evaluate the amount of evidence
available for use of these existing PROs in
patients with GenPs. The literature review
results and subsequent gap analysis led to cre-
ation of the draft Symptom Numeric Rating
Scale (NRS) used in the qualitative patient
interviews, which were conducted using both
concept elicitation and cognitive debriefing
methods. The draft Symptom NRS that was used
in the elicitation interviews was then modified
on the basis of the patient input. Cognitive
debriefing was then conducted on the final
instrument using a second multinational set of
patients with GenPs.
Literature Review
To identify peer-reviewed articles and PROs that
were relevant to symptoms of psoriasis and
GenPs, we performed a search of literature,
conference proceedings, and recent clinical tri-
als (Table S1 in the supplementary material).
The search was limited to English-language
publications that were published between 2005
and February 2015 and conference abstracts
that were published between 2011 and February
2015; both were indexed in EMBASE/Medline.
The clinical trial search was limited to future or
active clinical trials listed in www.clinicaltrials.
gov between 2013 and 2015.
Input from Clinicians
Two clinicians including one author (CR) of this
manuscript were interviewed to confirm GenPs
symptoms most relevant to patients as gleaned
from the literature review and to endorse the
use of specific PROs to assess these symptoms in
GenPs patients. The purpose was to discuss
patient symptoms and possibly relevant PROs
from the perspective of clinicians with many
years of experience treating patients with pso-
riasis and GenPs. Both clinicians specialize in
dermatology, practice in the USA, have exper-
tise in GenPs, and have experience in the con-
duct of clinical trials involving psoriasis
patients.
Draft Symptom NRS Items
The draft Symptom NRS items (questions) were
adapted from the Itch NRS [17]. The Symptom
NRS items separately assess itch, pain, discom-
fort, and stinging/burning, each on an 11-point
scale ranging from 0 (‘‘none’’) to 10 (‘‘worst
severity imaginable’’) (Table 1). Participants
were asked to indicate the overall severity of the
symptom by circling the number that best rep-
resented the worst symptom level they had
experienced in the past 24 h. Two versions were
debriefed: one focused on general psoriasis
symptoms, and the other focused on GenPs
symptoms.
Qualitative Interviews
The site investigator and clinical personnel
identified potential participants by reviewing
patient charts and patient databases and by
speaking to patients either during scheduled
visits to their doctor or over the phone. At
screening, eligible participants were adults aged
at least 18 years with confirmed chronic plaque
psoriasis of at least 6 months’ duration who had
an affected body surface area of at least 1% and
a current or recent history (within 3 months) of
moderate or severe genital involvement (Patient
Global Assessment score C 4 on a 6-point scale
from 0 to 5), as reported by the patient and
confirmed by the site investigator via medical
records. Completion of the patient-reported
patient global assessment of symptom severity
in the genital area was required as part of the
screening process to allow the site to confirm
current or recent severity of GenPs, either in
person at a scheduled visit to their doctor’s
office or by telephone. The assessment area
included the penis, scrotum, and perineum for
males and the labia majora, labia minora, and
perineum for females. In addition, participants
must have failed to respond to or been intoler-
ant of at least one topical therapy for GenPs.
Participants were recruited from five clinical
sites located in Arkansas, Indiana, Michigan,
and Washington. In-person or telephone inter-
views (one-on-one) were planned. A semistruc-
tured guide was used. The interviews, which
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were conducted between August 19, 2015 and
November 19, 2015, were audio-recorded,
transcribed, and deidentified. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. Informed consent for
audio recording was obtained from all subjects
for being included in the study, although the
local institutional review board (Chesapeake
IRB, Columbia, MD, USA) had determined that
the study was exempt. Packets containing study
materials and the informed consent form were
mailed to participants before the scheduled
interviews.
The interviews consisted of both concept
elicitation and cognitive debriefing compo-
nents. During the elicitation portion, partici-
pants discussed GenPs-associated symptoms
and severity with trained interviewers; the
responses were sometimes spontaneous and
sometimes probed. Completion of and discus-
sion of the draft Symptom NRS items were
conducted during the cognitive debriefing por-
tion of the interview; this included discussions
of the draft, including item clarity, ease of use,
mode of administration, and frequency of
administration. Each interview was conducted
in a single session that lasted approximately
2 h; participants were remunerated for their
time.
Table 1 Draft Symptom Numeric Rating Scale
Itch Numeric Rating Scale
1. Please rate your itching severity due to your [genital] psoriasis by circling the number that best describes your worst level
of itching in the past 24 h
0 1 2 3 4 5 6 7 8 9 10
No itch Worst itch imaginable
Pain Numeric Rating Scale
2. Please rate your pain severity due to your [genital] psoriasis by circling the number that best describes your worst level of
pain in the past 24 h
0 1 2 3 4 5 6 7 8 9 10
No pain Worst pain imaginable
Discomfort Numeric Rating Scale
3. Please rate your discomfort severity due to your [genital] psoriasis by circling the number that best describes your worst
level of discomfort in the past 24 h
0 1 2 3 4 5 6 7 8 9 10
No discomfort Worst discomfort imaginable
Stinging/Burning Numeric Rating Scale
4. Please rate your stinging/burning severity due to your [genital] psoriasis by circling the number that best describes your
worst level of stinging or burning in the past 24 h
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Item Refinement
A panel of PRO and GenPs experts modified the
draft Symptom NRS items on the basis of results
from the content analysis and after review of
transcripts from the participant interviews.
Subsequently, the GPSS was finalized for routine
practice and clinical trial use for evaluation of
the symptoms that are most important to GenPs
patients. Cognitive debriefing interviews were
then conducted to confirm language compre-
hension and cultural appropriateness of the
GPSS items.
Cognitive debriefing and cultural adapta-
tion/translation interviews were conducted
with a second group of 50 participants with self-
reported GenPs ranging in age from 18 to
82 years (average 45.7 years). These participants
were from seven countries and one US territory
(Australia, Austria, Belgium, Canada, the
Netherlands, Puerto Rico, Turkey, and USA),
and 44% were male. Before the cognitive
debriefing interviews, participants were asked to
review the GPSS and circle any text that was
difficult to comprehend. During the interviews,
participants were asked to identify any circled
text that they found difficult to understand and
asked to explain why. The participants were
then guided line-by-line through the GPSS by
the interviewer and asked to paraphrase each
item. If a subject had difficulty understanding
any text or a concept, the interviewers attemp-
ted to determine the reason and requested
suggestions for rewording the difficult text.
Data Analysis
A content analysis approach was used to ana-
lyze the qualitative data from the concept elic-
itation interviews, which were based on notes,
transcripts, and audio recordings. ATLAS.ti ver-
sion 7.5.9 (Scientific Software Development
GmbH, Berlin, Germany) was used to analyze
the interview transcripts. This software system-
atically identifies themes within qualitative
data. This enabled the development of a coding
dictionary, which was based on the semistruc-
tured interview guide. We also qualitatively
analyzed the participant evaluations of the draft
and final items for clarity, comprehensiveness,
relevance, and understandability.
Cohen’s kappa (j), which assesses the level of
agreement between two measures, was used to
assess concordance between the general psoria-
sis and the GenPs-specific Symptom NRS items.
Values between 0.40 and 0.75 represent fair-to-
good agreement, and values greater than 0.75
represent excellent agreement [18].
RESULTS
Literature Search, Expert Input, and Gap
Analysis
Overall, the literature search yielded 260 articles
or abstracts. Of these, 52 articles, 44 abstracts,
and 41 clinical trials met predefined search cri-
teria. Among the articles, the most common
psoriasis or GenPs symptoms reported were itch
(mentioned by 50% of examined articles), pain
(46.2%), redness/erythema (40.4%), scaling
(36.5%), and stinging/burning (30.8%). ‘‘Dis-
comfort’’ was mentioned in nine articles
(17.3%) but was not defined. Abstract results
were generally consistent with those of articles.
The most relevant instruments were the Itch
Visual Analogue Scale and NRS, the Psoriasis
Symptom Inventory (PSI), the Psoriasis Symp-
tom Diary (PSD), and the Self-Administered
Psoriasis Area and Severity Index (SAPASI).
The symptoms of itch and burning identified
during the literature search were confirmed as
the most relevant by clinical experts, who also
confirmed that the other identified symptoms
from the review were relevant and should be
considered important. The clinicians reported
that from their experience, itching and burning
were the most bothersome symptoms for
patients. Additional signs and symptoms were
discomfort, described as an ‘‘uncomfortable’’,
‘‘dull’’, or ‘‘burning sensation’’; pain, including
dyspareunia; redness; ulceration; and erosion.
Both clinicians agreed with selection of itch,
pain, discomfort, redness, stinging, and burning
as GenPs-related symptoms, but they differed
on the inclusion of ‘‘scaling’’. Additional rec-
ommended symptoms for inclusion were dys-
pareunia, pain on defecation, erosion/
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ulceration, inflammation, bleeding, tearing,
and sensitivity. Both clinicians also agreed with
conducting a gap analysis on the PROs (Itch
NRS, PSI, PSD, and SAPASI) identified during the
literature review, but one clinician indicated
that the SAPASI may be challenging for GenPs
patients because of the small area of bodily
involvement.
A gap analysis assessed the content validity
and psychometric properties of the PROs that
were identified in the literature search and the
extent to which each PRO met the Food and
Drug Administration evidentiary standards for
clinical trial use [19]. The chosen PROs had
documented evidence supporting item concep-
tualization history, reliability, validity, and
responsiveness [17, 20–26]. According to this
analysis, the PSI and PSD were the most appro-
priate for assessing symptom severity of psoria-
sis but could not be used because of limitations
on their use at the time that this study was
developed. The SAPASI covers a narrow range of
symptoms so was not easily adapted to GenPs.
On the basis of the clinician input and the gap
analysis, an adapted form of the Itch NRS for
psoriasis was selected for inclusion in the qual-
itative study to assess the relevant symptoms of
GenPs (Table 1).
Participant Interviews and Development
of Final PRO
Twenty-five participants were screened, and 22
met the study criteria; of these, 20 participants
were interviewed because two were unavailable
because of scheduling issues. Table 2 shows
baseline demographics. All participants
declined in-person interviews, so the interviews
were conducted by telephone.
In the interviews, GenPs was defined as
psoriasis occurring on the penis, scrotum, and
‘‘area between the penis and the anus’’ (per-
ineum) for males and on the ‘‘outer lip’’ (labia
majora), ‘‘inner lip’’ (labia minora), and ‘‘area
between the vagina and the anus’’ (perineum)
for females. Table 3 lists sample interview
questions. During the interviews, all partici-
pants reported that itch and discomfort were
associated with their GenPs; other symptoms,
mentioned either in spontaneous comments or
after probing from the interviewer, included
redness/erythema (95%; n = 19), stinging/
burning (95%; n = 19), pain (85%; n = 17), and
scaling (75%; n = 15). Spontaneously reported
symptoms included itch (90%; n = 18), redness/
erythema (50%; n = 10), stinging/burning
(45%; n = 9), pain (40%; n = 8), and cracking
(30%; n = 6). The most bothersome symptoms
were itch (40%; n = 8), stinging/burning (40%;
n = 8), and pain (20%; n = 4). Participants dif-
ferentiated between ‘‘pain’’ and ‘‘discomfort’’ by
taking into account that ‘‘discomfort’’ had both
physical and emotional (anguish) connotations.
Some participants described ‘‘stinging/burning’’
collectively, but others distinguished between
the two.
The general psoriasis Symptom NRS and
GenPs Symptom NRS items had fair-to-good
agreement for itch (j = 0.40), discomfort
(j = 0.55), and stinging/burning (j = 0.61);
they had excellent agreement for pain
(j = 0.77). Although participants reported that
both sets of items reflected their GenPs symp-
toms, more participants indicated that the
location-specific item (‘‘due to your genital
psoriasis’’) reflected their GenPs better than the
general item (‘‘due to your psoriasis’’). A 24-h
recall period was considered adequate by most
participants (55%; n = 11).
Item Refinement and Development
of GPSS
On the basis of the patient interviews, the draft
Symptom NRS items were modified for use in
clinical trials and in clinical practice, resulting
in the GPSS. The GPSS defines the genital area as
‘‘the penis, scrotum, and perineum (area
between the penis and anus) for males’’ and as
‘‘the labia majora (outer lips), labia minora (in-
ner lips), and perineum (area between vagina
and anus) for females’’. The GPSS contains eight
items regarding GenPs symptoms and has a
recall period of 24 h (Table 4). The items sepa-
rately address itch, pain, discomfort, stinging,
burning, redness, scaling, and cracking on an
11-point scale where 0 represents ‘‘no symp-
tom’’ and 10 represents ‘‘worst symptom
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Table 2 Patient demographics
Characteristics Number of patients responding n (%) or mean (SD)
Age, years [mean (SD)] 20 45 (14.2)
Sex, n (%) 20
Female – 11 (55)
Race, n (%) 20
White – 18 (90)
Black or African American – 1 (5)
Multiple races – 1 (5)
BSA score, mean (SD) 15 10.4 (12.7)
Duration of genital psoriasis, years [mean (SD)] 20 7.5 (9.7)
Duration of psoriasis, years [mean (SD)] 19 18 (14)
Sexual activity status, n (%) 20 –
Not active – 9 (45)
Active – 9 (45)
Not askeda – 2 (10)
Self-reported severity of overall psoriasis symptoms (worst over past 3 months), n (%) 20 –
0 (clear) – 0
1 – 1 (5)
2 – 1 (5)
3 – 5 (25)
4 – 5 (25)
5 (severe) – 8 (40)
Self-reported severity of genital psoriasis symptoms (worst over past 3 months), n (%)b 20 –
0 (clear) – 0
1 – 0
2 – 1 (5)
3 – 5 (25)
4 – 8 (40)
5 (severe) – 6 (30)
Self-reported general health within past week, n (%) 20 –
Excellent – 2 (10)
Very good – 4 (20)
Good – 11 (55)
Fair – 3 (15)
Poor – 0
Currently receiving treatment for overall psoriasis, n (%) 20 14 (70)
BSA body surface area
a The question was not asked because of conversation flow, auditory cues, and subject’s apparent lack of comfort with sensitive topics per interviewer judgment
b All participants met eligibility criteria (Patient Global Assessment C 4, 6-point scale from 0 to 5) at time of screening; the table reflects responses at the time of the
interview
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imaginable’’. Each of the eight items are scored
separately; in addition, a total score ranging
from 0 (no GenPs symptoms) to 80 (worst
imaginable GenPs symptoms) is reported. If any
item score is missing, the GPSS total score will
be missing.
Cognitive debriefing and cultural adapta-
tion/translation interviews were conducted on
the final version of the GPSS. In the cultural
adaptation/translation component, there were
no issues with the English-language version,
and some minor changes were made in the
Spanish and French versions. Overall, the GPSS
items had confirmed clarity, comprehensive-
ness, relevance, and understandability.
DISCUSSION
Here we reported the development of a new
PRO, the GPSS. This multiple item instrument
was modeled after the Itch NRS, which contains
a single item pertaining to the severity of itch
during the previous 24 h [17]. The GPSS was
designed to measure the severity of multiple
symptoms specific to GenPs. Whereas multiple
PROs are available to measure symptoms of
patients with general psoriasis, the GPSS
directly addresses a specific disease manifesta-
tion of psoriasis that is particularly burdensome
to patients. Patients with GenPs report sub-
stantial physical and psychosocial distress, and
it has been suggested that improvements should
be made in both physical and psychological
support for these patients [12]. To this end, a
tool that can be used to assess GenPs symptoms
during treatment is needed. The GPSS has
applicability to both clinical trials and routine
clinical practice.
The work described here establishes content
validation of the GPSS. Content validation is an
initial step in the development of a new PRO,
and this work was conducted in accordance
with applicable guidelines and best research
practices [19, 27, 28]. During the patient inter-
views, participants reported that the draft
Symptom NRS items that specifically men-
tioned GenPs were more relevant to their con-
dition. However, on the basis of patient
interviews, items of the draft Symptom NRS
Table 3 Sample interview questions
Concept elicitation: symptom experience
What symptoms do you experience with your genital psoriasis?
How would you describe [symptom]?
How frequently do you experience [symptom]?
How severe is the [symptom]?; How long does your [symptom] typically last?
Concept elicitation: bother assessment
Thinking specifically about your genital psoriasis, which of the symptoms that we have discussed are most bothersome or
affect you the most? Why?
Cognitive debriefing
What do you think about the scale? When responding to the question, what did you consider when selecting your
answer?
What do you think about the instructions? Are there words in the instructions that need to be clearer?
Please look at the response options 0 [no (symptom)] to 10 [worst (symptom) imaginable]. Are you able to rate your
[symptom] using these response options?
What do you think about the recall period of the questions—the past 24 h? What do you think about that amount of
time?
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were modified to separate stinging/burning into
two items and to add redness, scaling, and
cracking, leading to the final version of the
GPSS. Each of the eight individual items
receives a score of 0–10 and is reported as item
scores for itch, pain, discomfort, stinging,
burning, redness, scaling, and cracking. In
addition, a total score ranging from 0 (no GenPs
symptoms) to 80 (worst imaginable GenPs
symptoms) is reported. The GPSS has a recall
period of 24 h. The measure is culturally
appropriate, easy to use and understand, and
can be completed by patients either on paper or
electronically. Finally, the measure is specific to
GenPs and considers the symptomology of an
underserved group of patients.
The definition of GenPs used here was pre-
cisely defined in both male and female patients
on the basis of guidance from advisors and in
consideration of the areas defined in the modi-
fied Genital Psoriasis Area and Severity Index
[3, 29]. In clinical practice patients may present
with psoriasis in adjacent areas of the inguinal
region and in the rima ani; however, the
instrument itself clearly defines GenPs to ensure
consistency when used in clinical trial settings.
This work does have a few limitations,
including generalization to all patients with
GenPs. Racial minorities, notably African
Americans, were underrepresented during con-
cept elicitation. The concept elicitation inter-
views were conducted in late summer and fall,
but psoriasis flares can be seasonal [30]. Finally,
the work described here is only qualitative, so
the psychometric properties of the GPSS must
still be evaluated to determine its validity, reli-
ability, and ability to measure changes of pso-
riasis symptoms.
CONCLUSIONS
The GPSS provides a means for patients to
communicate GenPs symptoms in a manner
Table 4 Genital Psoriasis Symptoms Scale (GPSS)
Rating of severity based on your psoriasis symptoms in the genital areaa
within the past 24 h
Response options
Itchingb No itch (0)–worst itch imaginable (10)
Painb No pain (0)–worst pain imaginable (10)
Discomfortb No discomfort (0)–worst discomfort
imaginable (10)
Stingingb No stinging (0)–worst stinging imaginable
(10)
Burningb No burning (0)–worst burning imaginable
(10)
Rednessb No redness (0)–worst redness imaginable
(10)
Scalingb No scaling (0)–worst scaling imaginable
(10)
Crackingb No cracking (0)–worst cracking
imaginable (10)
For permission to reproduce or use the GPSS, please contact copyright@lilly.com
a Genital area is defined as the labia majora (outer lips), labia minora (inner lips), and perineum (area between vagina and
anus) for females and the penis, scrotum, and perineum (area between the penis and anus) for males
b Please rate your symptom severity due to your genital psoriasis by selecting the number that best describes your worst level
in the past 24 h
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that is less personally invasive than in-person
discussions by using paper or an electronic
device. As such, the GPSS may help solicit
information relevant to the understanding of
the burden of GenPs on individuals, and its use
can facilitate discussion with patients and gar-
ner information needed to make treatment
decisions and to monitor the success of treat-
ment in both clinical trials and routine practice.
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